Main Products/ Services/ Pipelines & Platforms
TLC BioSciences is a late clinical stage specialty pharmaceutical company. At TLC, we are dedicated to the research, development, and commercialization of novel nanomedicines that maximize the potential of our proprietary lipid-assembled drug delivery platforms (LipAD®). With three approved drugs in our track record, our expertise in liposome science allows for a combination of rapid onset and extended benefit duration, enhancing active drug concentrations while minimizing systemic exposures.
Our BioSeizer® technology enables local sustained release of therapeutic agents at the site of disease or injury. Our NanoX® active drug loading technology alters systemic exposure and potentially reduces dosing frequency. Our new early-stage assets include gene therapy and lipid nanoparticle (LNP) treatments with the potential to regenerate cells.
Versatile in active pharmaceutical ingredients and scalable in manufacturing, these technologies address unmet medical needs in orthopedics and pain management.
Pipeline: ♦ Orthopedics: ▪ TLC599 (osteoarthritis pain relief) ▪ TLC590 (postsurgical local analgesic) ▪ TLC504/503/502/501 (gene therapy)
♦ Others: ▪ Ampholipad® (systemic fungal infections) ▪ TLC399 (macular edema) ▪ TLC178 (advanced malignancies / soft tissue sarcoma) ▪ TLC19 (lung diseases)
Business Interests
▪ Out-Licensing ▪ Collaborative R&D
Contact Info
Ms. Dawn Chi
Corporate & Medical Communications
+886-2-2655-7377 ext.136
dawn@tlcbio.com